Zacks Research Weighs in on Aethlon Medical FY2026 Earnings

Aethlon Medical, Inc. (NASDAQ:AEMD) – Equities researchers at Zacks Research dropped their FY2026 EPS estimates for Aethlon Medical in a note issued to investors on Wednesday, February 18th. Zacks Research analyst M. Marin now expects that the medical equipment provider will post earnings of ($10.40) per share for the year, down from their prior forecast of ($9.41). The consensus estimate for Aethlon Medical’s current full-year earnings is ($0.73) per share. Zacks Research also issued estimates for Aethlon Medical’s Q4 2026 earnings at ($2.47) EPS.

Aethlon Medical (NASDAQ:AEMD) last released its quarterly earnings data on Thursday, February 12th. The medical equipment provider reported ($2.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.01) by ($0.44).

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Aethlon Medical in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Aethlon Medical has a consensus rating of “Reduce” and an average price target of $560.00.

Aethlon Medical Trading Down 1.5%

Shares of Aethlon Medical stock opened at $2.01 on Friday. Aethlon Medical has a twelve month low of $1.86 and a twelve month high of $49.58. The stock has a market cap of $2.65 million, a price-to-earnings ratio of -0.14 and a beta of 1.60. The company has a fifty day moving average price of $2.56 and a 200 day moving average price of $5.92.

Hedge Funds Weigh In On Aethlon Medical

An institutional investor recently bought a new position in Aethlon Medical stock. Citadel Advisors LLC bought a new stake in shares of Aethlon Medical, Inc. (NASDAQ:AEMD) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned about 36.57% of Aethlon Medical at the end of the most recent quarter. 1.99% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Aethlon Medical

Here are the key news stories impacting Aethlon Medical this week:

• Positive Sentiment: HC Wainwright raised several multi‑quarter and multi‑year EPS forecasts (FY2027–FY2030 and a series of 2027 quarterly forecasts), signaling the firm expects gradually improved results over the medium term. This could support sentiment if Aethlon executes on its plan. HC Wainwright estimate changes
• Neutral Sentiment: A shareholder/analyst call prepared remarks transcript was published (useful for detail on strategy, pipeline and management commentary) — may inform investors but contains no immediate market-moving announcement. Shareholder/Analyst Call Transcript
• Neutral Sentiment: Daily short-interest notices flagged a “large increase” in February but the reported short‑interest figure is 0 shares and days‑to‑cover shows 0.0 — the data look inconsistent/possibly erroneous, so there is no clear short‑squeeze or added short pressure indicated by these notices.
• Negative Sentiment: Zacks Research lowered Q4 2026 and FY2026 EPS estimates materially (Q4 to roughly ($2.47) and FY2026 to ($10.40) in their model), reducing near‑term expectations and adding short‑term negative pressure on sentiment. Zacks estimate cuts
• Negative Sentiment: Recent quarterly results showed a significant EPS miss (AEMD reported a large loss vs. consensus), and consensus full‑year estimates remain negative — these fundamentals help explain continued selling pressure and depressed valuation metrics.

About Aethlon Medical

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.